Trials / Completed
CompletedNCT02291471
Tolerance and Pharmacokinetics of T0001 in Healthy Adult Chinese Volunteers
An Open, Dose Escalation, Single Dose Study to Assess Tolerance and Pharmacokinetics of T0001 in Healthy Adult Chinese Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 56 (actual)
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study to assess the MTD and Pharmacokinetics of T0001 in Healthy Adult Chinese Volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | T0001，10mg | |
| DRUG | T0001，20mg | |
| DRUG | T0001，35mg | |
| DRUG | T0001，50mg | |
| DRUG | T0001，65mg | |
| DRUG | T0001，75mg |
Timeline
- Start date
- 2014-10-01
- Primary completion
- 2015-02-01
- Completion
- 2015-02-01
- First posted
- 2014-11-14
- Last updated
- 2019-07-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02291471. Inclusion in this directory is not an endorsement.